Ocugen Inc. (OCGN) shares are climbing on Friday, riding a wave of enthusiasm following clinical trial results that could reshape treatment options for a serious eye disease.

The Clinical Data Driving Investor Interest

Ocugen reported encouraging interim results this week from its Phase 2 ArMaDa trial evaluating OCU410 for geographic atrophy, a progressive form of age-related macular degeneration. The data showed a 46% reduction in lesion growth compared to the control group after 12 months, with no serious safety concerns across Phase 1 and 2 trials.

Here's where it gets interesting: the medium dose produced the strongest effect, delivering a 54% reduction in lesion size, while the high dose showed a 36% decline. This supports the therapy's potential as a disease-modifying treatment and could offer an alternative to the frequently injected treatments currently available.

The company expects to release full Phase 2 data later this quarter. Looking ahead, Ocugen is targeting a Phase 3 trial launch in 2026, with a potential Biologics License Application filing planned for 2028.

Pipeline Progress Beyond Geographic Atrophy

Ocugen isn't putting all its eggs in one basket. The company advanced its broader pipeline with Phase 1 GARDian1 data for gene therapy OCU410ST in Stargardt disease, which was published in Nature Eye. The results demonstrated favorable 12-month safety, tolerability, and exploratory efficacy across patients with early to advanced disease.

Additionally, Ocugen secured a 2025 licensing agreement granting Kwangdong Pharmaceutical exclusive Korean rights to OCU400, its modifier gene therapy for retinitis pigmentosa. That's real revenue potential from international markets.

Technical Momentum Building

The stock is currently trading 17.7% above its 20-day simple moving average and 28.4% above its 100-day SMA, showing longer-term strength. Over the past 12 months, Ocugen shares have jumped 149.65% and are positioned closer to their 52-week highs than lows.

The RSI sits at 55.12, which falls into neutral territory, indicating the stock is neither overbought nor oversold. Meanwhile, the MACD is trading above its signal line, suggesting bullish momentum is intact.

Earnings Report on the Horizon

Investors are eyeing the next earnings report scheduled for March 4. Analysts are expecting a loss of 6 cents per share, slightly worse than the 5-cent loss from a year ago. Revenue, however, is projected at $1.12 million, up from $0.76 million year-over-year.

The stock carries a Buy rating with an average analyst price target of $6.78. Chardan Capital maintains a Buy rating with a $7.00 target as of September 19, 2025.

ETF Exposure Worth Watching

The Direxion Moonshot Innovators ETF (NYSE:MOON) holds Ocugen at a 2.35% weight. Because OCGN carries meaningful weight in this fund, any significant inflows or outflows will likely force automatic buying or selling of the stock, adding another layer of potential volatility.

Ocugen shares were up 8.64% at $1.76 at the time of publication on Friday, according to market data.